Showing 4161-4170 of 8826 results for "".
- Colloidal Oatmeal Cream Soothes AD in Black Childrenhttps://practicaldermatology.com/news/colloidal-oatmeal-cream-soothes-ad-in-black-children/2462018/Oatmeal cream may help ease atopic dermatitis in Black children, according to research presented at the Science of Skincare Summit in Austin, Texas. Black children are 1.7 times more likely to dev
- UCB Anticipates Delay for FDA Bimekizumab Decisionhttps://practicaldermatology.com/news/ucb-anticipates-delay-for-fda-bimekizumab-decision/2462017/The anticipated Biologics License Application (BLA) for bimekizumab to treat plaque psoriasis will likely be delayed beyond Q3 2023, according to a statement from UCB. Bimekizumab is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both interleukin 17A (IL-17A) an
- Does Vitiligo-associated Autoimmunity Reduce Morbidity and Mortality?https://practicaldermatology.com/news/does-vitiligo-associated-autoimmunity-reduced-morbidity-and-mortality/2462014/Vitiligo-associated autoimmunity may play a role in reducing morbidity and mortality, according to a study in the Journal of Investigative Dermatology. When researchers investigated the mortality of patients with vitiligo in a population-base
- Study: AD Ups Risk for IBDhttps://practicaldermatology.com/news/study-ad-ups-risk-for-ibd/2462009/Adults with atopic dermatitis (AD) have a 34% increased risk of developing new-onset inflammatory bowel disease (IBD) compared with individuals who do not have the skin condition, and children have a 44% increased risk, according to a new study from the P
- MTX vs. CsA in AD: Which Is Best for Kids?https://practicaldermatology.com/news/mtx-vs-csa-in-ad-which-is-best-for-kids/2462008/Methotrexate bested cyclosporine in children with severe atopic dermatitis, a new study shows. While new systemic therapies for AD are being introduced, researchers want to est
- Beyond BSA: IPC, NPF Call Attention to Psoriasis Lesion Location on Q of Lhttps://practicaldermatology.com/news/beyond-bsa-ipc-npf-call-attention-to-psoriasis-lesion-location-on-q-of-l/2462007/The International Psoriasis Council (IPC) is partnering with the National Psoriasis Foundation (NPF) to call attention to the influence of psoriasis lesion locations on patients’ quality of life. The joint effort presents a study that delves into how psoriasis in specific areas
- AD News: Lebrikizumab Clears Hurdle in EUhttps://practicaldermatology.com/news/ad-news-lebrikizumab-clears-hurdle-in-eu/2462005/The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for Almirall's EBGLYSS (lebrikizumab) for the treatment of adult and adolescent patients aged 12 and older with a body weight of at least 40 kg who have moderate
- A Livestock Drug Delivered Via Nanoparticles May Help Eradicate Acnehttps://practicaldermatology.com/news/a-livestock-drug-delivered-via-nanoparticles-may-help-eradicate-acne/2462004/Australian scientists may have found an effective treatment for acne that is delivered via tiny nanoparticles. In a study led by the
- Almirall Launches New Campaign, Atopic Museum for World Eczema Dayhttps://practicaldermatology.com/news/almirall-launches-new-campaign-atopic-museum-for-world-eczema-day/2462003/Almirall unveiled its atopic dermatitis awareness campaign "Moving aheAD" for World Atopic Eczema Day. The campaign includes the “Atopic M
- Arcutis Submits NDA for Roflumilast Cream 0.15% for AD Treatmenthttps://practicaldermatology.com/news/arcutis-submits-nda-for-roflumilast-cream-015-for-ad-treatment/2462001/Arcutis Biotherapeutics, Inc. submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for roflumilast cream 0.15% for the treatment of mild to moderate atopic dermatitis (AD) in adults and children ages 6 years and older. Roflumilast cream is